Brand Name

Conjupri

Generic Name
Levamlodipine
View Brand Information
FDA approval date: October 08, 2021
Form: Tablet

What is Conjupri (Levamlodipine)?

CONJUPRI ® is calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.

Approved To Treat

Top Global Experts

There are no experts for this drug

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

There is no clinical trials being done for this treatment

Related Latest Advances

Perioperative management of a patient with tuberculous destroyed lung and ascending aortic aneurysm undergoing a Bentall procedure: a case report.
Perioperative management of a patient with tuberculous destroyed lung and ascending aortic aneurysm undergoing a Bentall procedure: a case report.
Journal: Frontiers in cardiovascular medicine
Published: December 07, 2025
The effect of danshen ligustrazine injection as adjuvant therapy on serum levels of salusins, catestatin, MMP-2, MMP-9, and TIMP-1 in patients with primary hypertension.
The effect of danshen ligustrazine injection as adjuvant therapy on serum levels of salusins, catestatin, MMP-2, MMP-9, and TIMP-1 in patients with primary hypertension.
Journal: BMC complementary medicine and therapies
Published: December 23, 2024
Model-Informed Precision Dosing of Levamlodipine Besylate in Smoking Patients.
Model-Informed Precision Dosing of Levamlodipine Besylate in Smoking Patients.
Journal: Drug design, development and therapy
Published: November 08, 2024
View All Latest Advances